Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-Center, Open Label, Single Arm, Multiple Dose Study to Assess the Tolerability，Pharmacokinetics and Efficacy of MIL62 in Chinese Patients With Relapsed/Refractory CD20+ Malignant B-cell Lymphomas

NCT04103905 is registered in ClinicalTrials.gov with Beijing Mabworks Biotech Co., Ltd. as lead sponsor.

NCT NCT04103905
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04103905 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-Center, Open Label, Single Arm, Multiple Dose Study to Assess the Tolerability，Pharmacokinetics and Efficacy of MIL62 in Chinese Patients With Relapsed/Refractory CD20+ Malignant B-cell Lymphomas
Lead sponsor
Beijing Mabworks Biotech Co., Ltd.
Phase
Phase 1
Overall status
Completed
Start date
February 10, 2017
Completion date
May 29, 2020
Enrollment
27 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cd20-positive b cell non-hodgkin lymphoma